Pioglitazone: Difference between revisions
| [unchecked revision] | [unchecked revision] |
MDElliottMD (talk | contribs) parser-claude batch MedTemplate pre-fill, Top 300 #133 |
MDElliottMD (talk | contribs) home-claude category backfill (parser-claude gap closure) |
||
| Line 21: | Line 21: | ||
== References == | == References == | ||
<references /> | <references /> | ||
[[Category:Thiazolidinediones]] | |||
[[Category:Antihyperglycemic agents]] | |||
[[Category:PPAR gamma agonists]] | |||
Latest revision as of 10:43, 23 May 2026
Pioglitazone
Actos
Experience
No personal reports yet
No clinical reports yet
Log in to add your own experience.
Problems
No problems yet. Be the first to suggest one.
+ Add a problemTitration strategies
No titration strategies yet. Be the first to suggest one.
Effects
No effects listed yet. Be the first to suggest one.
Relevant anecdote
No anecdotes yet. Share a relevant one.
Relevant Literature
No literature entries yet.
Log in to submit relevant literature.
Summary
Common uses
Type 2 diabetes mellitus0, NASH/MASH (off-label, with insulin resistance phenotype)0
Pharmacy
Starting dose
15-30 mg PO once daily; titrate to 45 mg
Preparations
15, 30, 45 mg tablets
US FDA Max
45 mg/d
Pharmacology
Routes
Oral
Onset
HbA1c effect at 12-16 weeks (slower than other classes)
Duration
24 hours
Half-life
~3-7 hours (parent); 16-24 hours including active metabolites[1]
Bioavailability
High (oral; absorption not affected by food)[1]
Pregnancy
Limited data; switch to insulin where feasible.[citation needed]
Legal status
Purported mechanism
Pioglitazone is a selective agonist of peroxisome proliferator-activated receptor γ (PPAR-γ); the activated receptor remodels transcription of adipocyte differentiation, lipid storage, and insulin-sensitivity genes, lowering insulin resistance with effects on free fatty acid handling, adiponectin secretion, and inflammatory tone.0 Mechanism is insulin-sensitizing rather than insulin-secretagogue, so monotherapy hypoglycemia risk is low. Characteristic adverse effects: fluid retention (HF precipitation), weight gain, distal bone fracture risk (especially in women), and a small bladder cancer signal historically debated; benefit in NASH/MASH and the IRIS trial's stroke recurrence benefit in insulin-resistant non-diabetics keep pioglitazone clinically interesting[1].
References
- ↑ 1.0 1.1 1.2 1.3 FDA Prescribing Information, Actos (pioglitazone HCl), Takeda, current revision. https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/021073s055lbl.pdf